{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:43:17Z","timestamp":1779205397944,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,18]]},"DOI":"10.7759\/cureus.56358","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T08:26:48Z","timestamp":1710750408000},"source":"Crossref","is-referenced-by-count":1,"title":["Acute Exacerbation of Idiopathic Pulmonary Fibrosis With Concurrent Cardiac Amyloidosis: A Technetium Pyrophosphate Study"],"prefix":"10.7759","author":[{"given":"Toyoshi","family":"Yanagihara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikaru","family":"Hatashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Moriuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Ishimatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atushi","family":"Moriwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01504-2015","article-title":"Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada","volume":"48","author":"Hopkins RB","year":"2016","unstructured":"Hopkins RB, Burke N, Fell C, Dion G, Kolb M. Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada. Eur Respir J. 2016, 48:187-95. 10.1183\/13993003.01504-2015","journal-title":"Eur Respir J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(14)70101-8","article-title":"Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11","volume":"2","author":"Raghu G","year":"2014","unstructured":"Raghu G, Chen SY, Yeh WS, Maroni B, Li Q, Lee YC, Collard HR. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med. 2014, 2:566-72. 10.1016\/S2213-2600(14)70101-8","journal-title":"Lancet Respir Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00354-4","article-title":"Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"10","author":"Naccache JM","year":"2022","unstructured":"Naccache JM, Jouneau S, Didier M, et al.. Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022, 10:26-34. 10.1016\/S2213-2600(21)00354-4","journal-title":"Lancet Respir Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic amyloidosis recognition, prognosis, and therapy: a systematic review","volume":"324","author":"Gertz MA","year":"2020","unstructured":"Gertz MA, Dispenzieri A. Systemic amyloidosis recognition, prognosis, and therapy: a systematic review. JAMA. 2020, 324:79-89. 10.1001\/jama.2020.5493","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson MM","year":"2020","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, et al.. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020, 142:e7-22. 10.1161\/CIR.0000000000000792","journal-title":"Circulation"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0046-2017","article-title":"The lung in amyloidosis","volume":"26","author":"Milani P","year":"2017","unstructured":"Milani P, Basset M, Russo F, Foli A, Palladini G, Merlini G. The lung in amyloidosis. Eur Respir Rev. 2017, 26:170046. 10.1183\/16000617.0046-2017","journal-title":"Eur Respir Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2021.101400","article-title":"Pulmonary amyloidosis complicated with pulmonary hemosiderosis, diagnosed with bronchoscopy","volume":"33","author":"Ogo N","year":"2021","unstructured":"Ogo N, Yanagihara T, Nishimura R, et al.. Pulmonary amyloidosis complicated with pulmonary hemosiderosis, diagnosed with bronchoscopy. Respir Med Case Rep. 2021, 33:101400. 10.1016\/j.rmcr.2021.101400","journal-title":"Respir Med Case Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-20-0110","article-title":"JCS 2020 guideline on diagnosis and treatment of cardiac amyloidosis","volume":"84","author":"Kitaoka H","year":"2020","unstructured":"Kitaoka H, Izumi C, Izumiya Y, et al.. JCS 2020 guideline on diagnosis and treatment of cardiac amyloidosis. Circ J. 2020, 84:1610-71. 10.1253\/circj.CJ-20-0110","journal-title":"Circ J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline","volume":"192","author":"Raghu G","year":"2015","unstructured":"Raghu G, Rochwerg B, Zhang Y, et al.. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015, 192:e3-19. 10.1164\/rccm.201506-1063ST","journal-title":"Am J Respir Crit Care Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/resp.14643","article-title":"Pulse versus non-pulse corticosteroid therapy in patients with acute exacerbation of idiopathic pulmonary fibrosis","volume":"29","author":"Hyung K","year":"2024","unstructured":"Hyung K, Lee JH, Kim JY, Choi SM, Park J. Pulse versus non-pulse corticosteroid therapy in patients with acute exacerbation of idiopathic pulmonary fibrosis. Respirology. 2024, 29:235-42. 10.1111\/resp.14643","journal-title":"Respirology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.37737\/ace.23006","article-title":"Efficacy of initial high- versus low-dose intravenous corticosteroid therapy in patients with acute exacerbation of idiopathic interstitial pneumonia: a nationwide observational study","volume":"5","author":"Awano N","year":"2023","unstructured":"Awano N, Jo T, Izumo T, et al.. Efficacy of initial high- versus low-dose intravenous corticosteroid therapy in patients with acute exacerbation of idiopathic interstitial pneumonia: a nationwide observational study. Ann Clin Epidemiol. 2023, 5:37-47. 10.37737\/ace.23006","journal-title":"Ann Clin Epidemiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00209-2022","article-title":"Effect of nintedanib on acute exacerbations of fibrosing interstitial lung diseases: a national database study in Japan","volume":"8","author":"Urushiyama H","year":"2022","unstructured":"Urushiyama H, Jo T, Hasegawa W, et al.. Effect of nintedanib on acute exacerbations of fibrosing interstitial lung diseases: a national database study in Japan. ERJ Open Res. 2022, 8:00209-2022. 10.1183\/23120541.00209-2022","journal-title":"ERJ Open Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2021.101385","article-title":"Three cases of sequential treatment with nintedanib following pulsed-dose corticosteroids for acute exacerbation of interstitial lung diseases","volume":"33","author":"Nakashima K","year":"2021","unstructured":"Nakashima K, Yanagihara T, Ishida S, Ogo N, Egashira A, Asoh T, Maeyama T. Three cases of sequential treatment with nintedanib following pulsed-dose corticosteroids for acute exacerbation of interstitial lung diseases. Respir Med Case Rep. 2021, 33:101385. 10.1016\/j.rmcr.2021.101385","journal-title":"Respir Med Case Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201909-1818OC","article-title":"Thrombomodulin alfa for acute exacerbation of idiopathic pulmonary fibrosis. A randomized, double-blind placebo-controlled trial","volume":"201","author":"Kondoh Y","year":"2020","unstructured":"Kondoh Y, Azuma A, Inoue Y, et al.. Thrombomodulin alfa for acute exacerbation of idiopathic pulmonary fibrosis. A randomized, double-blind placebo-controlled trial. Am J Respir Crit Care Med. 2020, 201:1110-9. 10.1164\/rccm.201909-1818OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2020-000558","article-title":"Efficacy of recombinant thrombomodulin for poor prognostic cases of acute exacerbation in idiopathic interstitial pneumonia: secondary analysis of the SETUP trial","volume":"7","author":"Arai T","year":"2020","unstructured":"Arai T, Kida H, Ogata Y, et al.. Efficacy of recombinant thrombomodulin for poor prognostic cases of acute exacerbation in idiopathic interstitial pneumonia: secondary analysis of the SETUP trial. BMJ Open Respir Res. 2020, 7:e000558. 10.1136\/bmjresp-2020-000558","journal-title":"BMJ Open Respir Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/cc12783","article-title":"A multicenter, prospective validation study of the Japanese Association for Acute Medicine disseminated intravascular coagulation scoring system in patients with severe sepsis","volume":"17","author":"Gando S","year":"2013","unstructured":"Gando S, Saitoh D, Ogura H, et al.. A multicenter, prospective validation study of the Japanese Association for Acute Medicine disseminated intravascular coagulation scoring system in patients with severe sepsis. Crit Care. 2013, 17:R111. 10.1186\/cc12783","journal-title":"Crit Care"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-017-0348-2","article-title":"Quantitative 3D scintigraphy shows increased muscular uptake of pyrophosphate in idiopathic inflammatory myopathy","volume":"7","author":"Th\u00f8gersen KF","year":"2017","unstructured":"Th\u00f8gersen KF, Simonsen JA, Hvidsten S, et al.. Quantitative 3D scintigraphy shows increased muscular uptake of pyrophosphate in idiopathic inflammatory myopathy. EJNMMI Res. 2017, 7:97. 10.1186\/s13550-017-0348-2","journal-title":"EJNMMI Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-04753-7","article-title":"Extracardiac soft tissue uptake, evidenced on early 99mTc-HMDP SPECT\/CT, helps typing cardiac amyloidosis and demonstrates high prognostic value","volume":"47","author":"Malka N","year":"2020","unstructured":"Malka N, Abulizi M, Kharoubi M, et al.. Extracardiac soft tissue uptake, evidenced on early 99mTc-HMDP SPECT\/CT, helps typing cardiac amyloidosis and demonstrates high prognostic value. Eur J Nucl Med Mol Imaging. 2020, 47:2396-406. 10.1007\/s00259-020-04753-7","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccas.2021.02.015","article-title":"Extracardiac accumulation of technetium-99m-pyrophosphate in transthyretin cardiac amyloidosis","volume":"3","author":"Takahashi K","year":"2021","unstructured":"Takahashi K, Sasaki D, Sakaue T, et al.. Extracardiac accumulation of technetium-99m-pyrophosphate in transthyretin cardiac amyloidosis. JACC Case Rep. 2021, 3:1069-74. 10.1016\/j.jaccas.2021.02.015","journal-title":"JACC Case Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-023-03310-7","article-title":"Prevalence and significance of extracardiac uptake on pyrophosphate imaging in the SCAN-MP study: the first 379 cases","volume":"30","author":"Chan N","year":"2023","unstructured":"Chan N, Einstein AJ, Griffin JM, et al.. Prevalence and significance of extracardiac uptake on pyrophosphate imaging in the SCAN-MP study: the first 379 cases. J Nucl Cardiol. 2023, 30:2531-9. 10.1007\/s12350-023-03310-7","journal-title":"J Nucl Cardiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/226772-acute-exacerbation-of-idiopathic-pulmonary-fibrosis-with-concurrent-cardiac-amyloidosis-a-technetium-pyrophosphate-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T08:26:51Z","timestamp":1710750411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/226772-acute-exacerbation-of-idiopathic-pulmonary-fibrosis-with-concurrent-cardiac-amyloidosis-a-technetium-pyrophosphate-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.56358","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,18]]}}}